TTHX1114(NM141) in Combination With DWEK/DSO
Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO
Sponsor: Trefoil Therapeutics, Inc.
A PHASE2 clinical study on Fuchs and Fuchs Dystrophy, this trial is completed. The trial is conducted by Trefoil Therapeutics, Inc. and has accumulated 10 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Oct 2023 — Dec 2023 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Feb 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — Feb 2022 [monthly]
Recruiting PHASE2
-
Jun 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Apr 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Trefoil Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .